Quarterly Financial Performance (Q4 FY26 vs Q4 FY25)

Revenue Performance:

  • Q4 FY26 Revenue: Rs 276.53 crore
  • Q4 FY25 Revenue: Rs 184.11 crore
  • Year-over-year growth: 50.2%

Profitability Metrics:

  • EBITDA Q4 FY26: Rs 97.62 crore (35.3% margin)
  • EBITDA Q4 FY25: Rs 67.58 crore (36.7% margin)
  • PAT Q4 FY26: Rs 74.23 crore (26.8% margin)
  • PAT Q4 FY25: Rs 50.37 crore (27.4% margin)
  • Quarterly EPS Q4 FY26: Rs 9.22
  • Quarterly EPS Q4 FY25: Rs 6.29

Annual Financial Performance (FY26 vs FY25)

Full Year Revenue:

  • FY26 Revenue: Rs 827.87 crore
  • FY25 Revenue: Rs 696.48 crore
  • Year-over-year growth: 18.9%

Full Year Profitability:

  • EBITDA FY26: Rs 294.05 crore (35.5% margin)
  • EBITDA FY25: Rs 260.79 crore
  • PAT FY26: Rs 209.12 crore (25.3% margin)
  • PAT FY25: Rs 187.96 crore (27.0% margin)
  • Annual EPS FY26: Rs 25.98
  • Annual EPS FY25: Rs 23.35

Segment-wise Performance

Therapeutic Segment Contribution:

  • Anesthetic segment: 54% of total revenues in FY26 (vs 49% in FY25)
  • Vitamins segment: 12% of total revenues in FY26 (vs 11% in FY25)

Geographical Revenue Distribution:

  • Europe: 40% of FY26 revenues, 44% of Q4 FY26 revenues
  • Asia: 33% of FY26 revenues, 34% of Q4 FY26 revenues
  • LATAM: 20% of FY26 revenues, 17% of Q4 FY26 revenues
  • Export contribution: Approximately 82% of FY26 revenues

Operational Highlights

Capacity Utilization:

  • FY26 capacity utilization: 74%
  • FY25 capacity utilization: 70%
  • Improvement driven by ramp-up of Module E at Lote facility and operational efficiencies

Product Development & Commercialization:

  • Commercialized Liquid Anesthetic product during FY26
  • Encouraging traction in newly launched products across cardiovascular and ADHD segments

Manufacturing Expansion:

  • Strategic land acquisitions near existing facilities and at Isambe, Patalganga
  • Ambernath formulation facility commissioned five finished dosage manufacturing lines
  • Progress on validation and dossier submission activities across multiple regulated markets

Management Commentary

Dr. Satish Wagh, Executive Chairman and Whole Time Director, stated: \"The strong performance delivered during Q4 FY26 and across the full year reflects steady demand across our key therapeutic segments, healthy traction in regulated markets, and continued operational focus across the business. Improved capacity utilisation, expansion in global markets, and contribution from newly launched products supported growth during the year. During FY26, we continued to strengthen our manufacturing and R&D infrastructure through capacity enhancement initiatives, strategic land acquisitions, and progress at our Ambernath formulation facility. The commercialisation of the Liquid Anesthetic product, advancement in our finished dosage capabilities, and continued focus on backward integration further strengthened the foundation of our business. With a diversified product portfolio, strong customer relationships across global markets, and ongoing investments in innovation and manufacturing capabilities, the Company remains well positioned to drive sustainable long-term growth.\"

Company Background

Supriya Lifescience Ltd. is a cGMP-compliant API manufacturer founded in 1987 with certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company operates in more than 120 countries globally with facilities in Mumbai (corporate office) and Khed, Ratnagiri (factory). The company holds eight active CEPs and fourteen active USDMFs, focusing on building intermediates and APIs for innovators and generic firms.